Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep
How do you know if a “positive” study is positive? And what if clinical trial…
Category: drug development
Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial
Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with…
STAT Plus: As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated…
STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
A group of leading Boston-area universities, hospitals, and corporations will create a new center for…
With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days…
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
CAMBRIDGE, Mass. — In his first appearance since Bristol-Myers Squibb completed its takeover last week…
STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates…
First CRISPR treatment for blood diseases shows early benefits in two patients
The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle…